Midostaurin, the first FDA approved targeted therapy in AML, is a non-selective first generation TKI that targets multiple other pathways including c-KIT, PKC, PDGFR, VEGFR, resulting in higher toxicity (13). The gene discussed is KIT; the disease is acute myeloid leukemia.